Table 1 Baseline characteristics of patients receiving ASCT for multiple myeloma.
Characteristics | Total n = 961 | HEPA group n = 480 | Non-HEPA group n = 481 | p value |
|---|---|---|---|---|
Median age, years (range) | 57 (28–76) | 56 (28–73) | 57 (28–76) | 0.002 |
Age, years | ||||
< 60 | 619 (64.4) | 329 (68.5) | 290 (60.3) | 0.008 |
≥ 60 | 342 (35.6) | 151 (31.5) | 191 (39.7) | |
Sex | ||||
Male | 528 (54.9) | 276 (57.5) | 252 (52.4) | 0.111 |
Female | 433 (45.1) | 204 (42.5) | 229 (47.6) | |
Duration from MM to HSCT ≥ 180 days | 667 (69.4) | 341 (71.0) | 326 (67.8) | 0.272 |
Comorbidities | ||||
Atrial fibrillation | 21 (2.2) | 10 (2.1) | 11 (2.3) | 0.829 |
Coronary artery disease | 248 (25.8) | 125 (26.0) | 123 (25.6) | 0.868 |
Liver cirrhosis | 26 (2.7) | 10 (2.1) | 16 (3.3) | 0.235 |
COPD | 260 (27.1) | 121 (25.2) | 139 (28.9) | 0.198 |
Cerebrovascular accidents | 110 (11.4) | 51 (10.6) | 59 (12.3) | 0.424 |
Diabetes mellitus | 275 (28.6) | 141 (29.4) | 134 (27.9) | 0.603 |
Hypertension | 486 (50.6) | 232 (48.3) | 254 (52.8) | 0.165 |
ESRD | 150 (15.6) | 63 (13.1) | 87 (18.1) | 0.034 |
Heart failure | 93 (9.7) | 47 (9.8) | 46 (9.6) | 0.905 |
Autoimmune disease | 90 (9.4) | 38 (7.9) | 52 (10.8) | 0.124 |
Stage | ||||
I | 122/477 (25.6) | 49/193 (25.4) | 73/282 (25.9) | 0.531 |
II | 159/477 (33.3) | 70/193 (36.3) | 89/282 (31.6) | |
III | 194/477 (41.1) | 74/193 (38.3) | 120/282 (42.6) | |
Degree of urbanization | ||||
Urban | 571 (59.4) | 288 (60.0) | 283 (58.8) | 0.899 |
Suburban | 321 (33.4) | 161 (33.5) | 160 (33.3) | |
Rural | 51 (5.3) | 24 (5.0) | 27 (5.6) | |
Unknown | 18 (1.9) | 7 (1.5) | 11 (2.3) | |
Income level | ||||
Low | 474 (49.3) | 230 (47.9) | 244 (50.7) | 0.621 |
Intermediate | 256 (26.6) | 129 (26.9) | 127 (26.4) | |
High | 231 (24.0) | 121 (25.2) | 110 (22.9) | |
